| Bioactivity | rel-VU6021625 is a relative configuration of VU6021625 (HY-160440A). VU6021625 is a potent and selective mAChR M4 antagonist with IC50 values of 0.44, 57, 5500, 3200, >10 000, >10 000 nM for human M4, rat M4, rat M1, rat M2, rat M3, rat M5 respectively. VU6021625 shows antiparkinsonian and antidystonic efficacy[1]. |
| Name | rel-VU6021625 |
| CAS | 2307718-96-1 |
| Formula | C25H32N6O |
| Molar Mass | 432.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Moehle MS, et al. Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy. ACS Pharmacol Transl Sci. 2021 Aug 2;4(4):1306-1321. |
rel-VU6021625
CAS: 2307718-96-1 F: C25H32N6O W: 432.56
rel-VU6021625 is a relative configuration of VU6021625 (HY-160440A). VU6021625 is a potent and selective mAChR M4 antago
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.